Detour Ahead: Incretin Hormone Signaling Alters Its Intracellular Path as β-Cell Failure Progresses During Diabetes

Mehboob A. Hussain 1*, Erinn Laimon-Thomson 1, Syed M. Mustafa 2, Alexander Deck 2 and Banya Song 1

1 Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI, United States, 2 College of Literature, Science and Arts, University of Michigan, Ann Arbor, MI, United States

Keywords: diabetes, beta cell dysfunction, KATP channel, GPCR coupling, incretin hormone

INTRODUCTION

The early events leading to β-cell failure during the pathogenesis of type 2 diabetes mellitus (T2DM) remain poorly understood (1). Upon glucose stimulation, insulin is released from β-cells in a biphasic manner with an initial first peak of insulin release (first phase), which – if the glucose stimulus persists – is followed by a second prolonged phase of insulin release (2–5). Defective first-phase insulin release is among the earliest markers that predict the development of T2DM (2–4). This defect persists in patients with T2DM and is also found in first-degree relatives of patients with T2DM (4). However, the molecular underpinnings of this particular defect have largely remained elusive. A recent report by Odouri et al. (6) now provides important new insight that may help understand the early stages in the development of β-cell dysfunction of T2DM. In this commentary we place these important findings (6) in the broader context of incretin hormone signaling and the early defects that occur in incretin action in β-cells during diabetes pathogenesis. We close by outlining new avenues for scientific inquiry, which the findings by Oudori et al. have opened with their observations.

STIMULUS-SECRETION COUPLING AND AMPLIFICATION OF INSULIN RELEASE

Gαs or Gαq Signaling-Dependent Mechanisms

Glucose-stimulated insulin secretion (GSIS) occurs through a cascade of precisely orchestrated electro-physiologic events in pancreatic β-cells (7, 8). Glucose transport into β-cells and enhanced glucose metabolism increase the cellular ATP/ADP ratio, leading to closing of ATP-sensitive K+ (KATP) channels. Restricted K+ exit through KATP channels depolarizes the β-cell plasma membrane, which in turn is followed by activation and opening of voltage dependent Ca2+ channels (VDCC). Calcium influx and thus increased cytoplasmic Ca2+ concentration in the β-cell, triggers insulin vesicle exocytosis (9–13).
GSIS is amplified by hormones and neurotransmitters, of which many function by activation of G-protein coupled receptors via trimeric G-proteins containing Goαs or Goαq, which signal, respectively, via cAMP and phospholipase C (PLC)-diacylglycerol (DAG)/-inositol 1, 4, 5-trisphosphate (IP3) (9, 14). Although both Goαs-cAMP and Goαq-PLC-DAG/IP3 are clearly recognized to amplify β-cell GSIS, the exact mechanisms of their signaling pathways, how they differ and where they overlap remain incompletely understood. Both Goαs-cAMP (via PKA-CREB activation) and Goαq-DAG-protein kinase C (PKC; via ERK1/2) activation increase IRS2 levels in β-cells, which is a central mediator in maintaining expression of PDX1 and other transcription factors that form a gene-regulatory network to maintain β-cell identity and maturity (15, 16). Goαs-cAMP and Goαq-PLC-dependent signaling pathways both regulate inositol tri-phosphate (IP3) receptor activity to mobilize calcium stored in the endoplasmic reticulum (ER) into the cytoplasm; and both PKA and PKC phosphorylate select SNARE (=soluble N-ethylmaleimide sensitive factor attachment protein receptor) complex proteins (i.e. SNAP25, MUNC18) to promote insulin vesicle exocytosis (17, 18). Thus, Goαs-PKA and Goαq-DAG-PKC signaling pathways converge on common targets that regulate GSIS amplification. Nevertheless, these two signaling systems fulfill distinct and non-redundant functions as β-cell-selective ablation of either Goαs (19) or Goαq (20) results in defective β-cell function or survival.

**THE CENTRAL ROLE FOR INCRETIN HORMONES IN REGULATING INSULIN SECRETION**

Critical for preventing postprandial hyperglycemia are the amplifying effects of the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose dependent insulinotropic peptide (GIP). Under physiologic conditions, the actions of these two incretin hormones are responsible for approximately 50% of insulin secretion after meal intake (21–23). GLP-1 and GIP are released from enteroendocrine L- and K-cells, respectively, upon nutrient stimulus in the intestine. Through the circulation they reach the pancreatic β-cells, where by activating their cognate G-protein coupled receptors, they potentiate glucose stimulated insulin release (21). The receptors for both GLP-1 (GLP-1R) and GIP (GIPR)—both abundantly expressed in β-cells, belong to the class B (secretin family) G-protein coupled receptors (GPCRs); and both couple primarily to the G-protein Goαs (21). Consequently, in the case of both hormones, binding and activation of their respective receptors stimulates intracellular cAMP synthesis and downstream signaling that is mediated by protein kinase A (PKA) and by the guanyl nucleotide exchange factor exchange protein activated by cAMP 2A (EPAC2A) (24). Cyclic AMP-PKA activation, via phosphorylation of PKA targets, stimulates multiple pathways within the β-cell that promote β-cell proliferation, survival, changes in gene expression as well as GSIS amplification. These are extensively reviewed elsewhere to which we refer the reader (21, 25) EPAC2A in β-cells, upon activation by cAMP translocates to the cytoplasmic membrane where it regulates exocytosis and mobilize intracellular calcium, thereby also amplifying GSIS (24, 26).

In this context, it is important to point out that in intestinal L-cells GLP-1 is produced through differential processing of proglucagon. More recently, there is increasing experimental evidence that GLP-1 may not only be produced in intestinal L-cells but also through differential posttranslational processing of proglucagon in pancreatic endocrine α-cells, where proglucagon is primarily processed to glucagon (27, 28). As such, GLP-1 produced in α-cells may also act on β-cells in a paracrine manner (27, 28). In certain experimental conditions, paracrine α- to β-cell signaling of proglucagon products appears to be critical for normal β-cell function. Furthermore, glucagon—the principal proglucagon-derived product in α-cells—binds to and activates both the glucagon receptor (GCGR) and GLP-1R (albeit with markedly reduced affinity as compared to GLP-1) on β-cells (29–32). Like the incretin hormone receptors, GCGR belongs to the class B secretin family of GPCRs, but couples to both Goαs and Goαq to stimulate, respectively cAMP- and DAG)/(IP3)-dependent signaling (33–35). GCGR-dependent signaling has been primarily described in hepatocytes (33–35) and - absent clinching experimental data - it remains unclear whether GCGR normally also signals via both Goαs and Goαq in β-cells.

Importantly, the loss of incretin hormone action in amplifying GSIS is an early characteristic of T2DM (23, 36–38). In individuals with defective first-phase insulin release and future risk of developing frank T2DM, pharmacologic GLP-1 receptor agonist treatment restores first-phase insulin secretion (39). However, quite early after the discovery of GLP-1 and GIP a remarkable difference was observed in their actions on β-cells of individuals with T2DM (22, 38). While treatment with GLP-1 potently amplifies GSIS in patients with T2DM, GIP treatment fails to do so; despite the fact that receptors of both of these hormones couple to Goαs to stimulate intracellular cAMP-dependent signaling. As a consequence of these observations, GLP-1 receptor agonists have quickly become a focus of scientific inquiry as well as of drug development for T2DM. Although clearly a key characteristic of β-cell failure in T2DM, the difference in action between GLP-1 and GIP in islets of T2DM has at the molecular level remained thus far unexplained.

**LINKING DEFECTIVE K<sub>ATP</sub> CHANNEL ACTIVITY AND DEFECTIVE INCRETIN HORMONE ACTION IN β CELLS**

The carefully conducted studies reported by Odouri et al. (6) provide a potential molecular explanation for the differences in GLP-1R and GIPR signaling in healthy β-cells versus those in T2DM. The initial focus of Odouri et al. was on the role of K<sub>ATP</sub> channels in β-cells versus those in T2DM. Partial loss of K<sub>ATP</sub> channels increases electrical excitability and insulin secretion, resulting in hyperinsulinemia in humans and in mice (42, 43). Complete loss of K<sub>ATP</sub> channels causes permanent depolarization and
chronically elevated intracellular Ca\(^{2+}\) concentrations at all glucose levels. However paradoxically and through unknown mechanisms, the absence of K\(_{\text{ATP}}\) channels results in a downregulation of insulin secretion and defective GSIS (42, 43).

Mice generated by Odouri et al. lack the pore-forming Kir6.2 component of the K\(_{\text{ATP}}\) channel specifically in β-cells (β-ΔKcnj11 mice), and confirming prior observations are actually glucose intolerant (6, 42, 43). Importantly however, GLP-1 effects on amplifying GSIS was partially retained while the effects of GIP were practically absent (6). These observations are remarkably similar to findings in humans who develop T2DM (see above).

**Signaling Detour for GLP-1R but Not for GIPR**

A key observation by Odouri et al. is that in these “hyper-excited” K\(_{\text{ATP}}\) channel-defective mouse islets, cAMP synthesis through GLP-1R or GIPR activation is markedly diminished. Importantly, while GIPR-dependent signaling is as a consequence practically silenced, the GLP-1R switches coupling from G\(_\alpha\)s to G\(_\alpha\)q, thereby engaging an alternate signaling pathway and allowing GLP-1 to potentiate GSIS in β-cell (6). In contrast GIPR fails to switch its coupling from G\(_\alpha\)s to G\(_\alpha\)q. Importantly, Odouri et al. show that GLP-1R does not couple through G\(_\alpha\)q in healthy control islets, but only in those with down-regulated K\(_{\text{ATP}}\) channel activity (6).

In additional studies Odouri et al. examined the KK-Ay mouse, which spontaneously develops a human T2DM-like phenotype. While β-cells from non-diabetic control KK mice showed normal electro-physiologic activity and patterns of GSIS, β-cells from KK-Ay mice were chronically depolarized and lacked GSIS. Treatment with GLP-1 but not with GIP amplified GSIS in KK-Ay islets. And GLP-1 effects were inhibited with the G\(_\alpha\)q antagonist FR900359 (It would help had the authors also examined the effects of the more specific G\(_\alpha\)q antagonist FR900359) (6). Thus, as in T2DM, in KK-Ay mice, β-cell GLP-1R but not GIPR signals via G\(_\alpha\)q while Gas-dependent signaling becomes defective.

The potential importance of these findings to understand β-cell failure in a broader context of T2DM comes with additional studies, in which Odouri et al. (6) expose both mouse and human islets to elevated glucose levels (as found in T2DM) for 3 to 5 days—a maneuver that causes chronic K\(_{\text{ATP}}\) channel closure (6, 44). Remarkably, when such treated islets were returned to lower (i.e. normoglycemic) glucose levels, their K\(_{\text{ATP}}\) channels remained suppressed and GSIS remained defective. However, similar to the observations made in β-ΔKcnj11 mice, GLP-1-induced GSIS potentiation was maintained, whereas GIP treatment had no such effect (6). And again, GLP-1 receptor signaling had switched from G\(_\alpha\)s to G\(_\alpha\)q coupling, whereas GIPR signaling had not made that switch.

These important observations by Odouri et al. provide a molecular explanation for the long known “incretin bias” in T2DM and link this particular phenomenon to a β-cell autonomous change in K\(_{\text{ATP}}\) channel activity (6, 44)—for which the underlying pathogenic mechanisms remain incompletely understood.

While the observations made by Odouri et al. provide experimental evidence that chronic (3–5 days) exposure to elevated glucose levels can lead to a down-regulation of K\(_{\text{ATP}}\) channel activity, it remains unclear whether other influences to which the β-cell is exposed in early T2DM pathogenesis (e.g., altered circulating lipid profiles, low level inflammation and likely additional as yet unrecognized factors) that precede hyperglycemia may also cause a down-regulation in K\(_{\text{ATP}}\) channel activity.

**DISCUSSION**

As all good science, the studies reported by Oduori et al. (6) have not only significantly advanced the field but also point in which direction to look further. The remarkable finding that in β-cells GLP-1R coupling switches during diabetes pathogenesis adds impetus to understand in more detail the mechanism and pathways of G\(_\alpha\)s- and G\(_\alpha\)q-dependent signaling in β-cell. Odouri et al. findings raise many questions related to incretin biology and to β-cell (dys-)function in T2DM pathogenesis as well as questions related to the treatment of β-cell dysfunction. Among these will undoubtedly be the following:

1. Are there circumstances in which a switch in GLP-1R coupling from G\(_\alpha\)s to G\(_\alpha\)q is of physiologic importance (as opposed to pathologic, i.e., diabetes mellitus)? The larger questions is whether the switch in GLP-1R coupling serves a particular physiologic purpose in the β-cell or whether this switch is a only manifestation of dysfunction and disease.
2. What are the intracellular mechanisms that underlie the switch from for G\(_\alpha\)s to G\(_\alpha\)q at the GLP-1R receptor? Insight into the molecular underpinnings of the switch from G\(_\alpha\)s to G\(_\alpha\)q would greatly enhance our understanding of changes in β-cell function early in the pathogenesis of diabetes mellitus.
3. How does G\(_\alpha\)q-mediated signaling lead to improved β-cell function, and how does it differ from G\(_\alpha\)s-mediated signaling in modulating β-cell function? G\(_\alpha\)s- and G\(_\alpha\)q-dependent signaling pathways converge at multiple levels. But their distinct roles remain poorly understood.
4. How does GLP-1R-G\(_\alpha\)s “uncoupling” and GLP-1R-G\(_\alpha\)q coupling modify β-cell proliferation survival, and maintenance of β-cell maturity? This question is an extension of the preceding question.
5. How does the glucagon receptor fare in the rochade from G\(_\alpha\)s to G\(_\alpha\)q coupling through GPCRs in β-cells? In T2DM, does glucagon receptor-dependent signaling also switch away from G\(_\alpha\)s and signal primarily via G\(_\alpha\)q? Glucagon uniquely activates both GLP-1R and GCGR (whereas GLP-1 does not activate GCGR). GCGR thus functions akin to an incretin hormone. Whether and how GCGR signaling changes during diabetes is unknown. The role of
glucagon in β-cell (dys-) function remains to be fully understood.

6. How do circulating lipids, circulating and local islet cytokines, intracellular alterations such as organelle (ER, mitochondria, Golgi apparatus) stress interplay with the silencing of Gøαs-coupling of incretin receptors and switch from Gøαs to Gøq signaling? Odouri et al. show that hyperglycemia causes a switch in GLP-1R coupling. Whether other participants in T2DM pathogenesis also promote this switch remains unclear.

7. Which therapeutic maneuvers will allow GLP-1R signaling of the failing β-cell to couple back with Gøαs and also reactivate GIPR signaling in β-cells?

The following three questions pertain to therapeutic approaches of β-cell dysfunction in light of the new findings by Odouri et al.

1. Would GLP-1R agonists that bias coupling through Gøq rather than Gøαs be more effective in treating β-cell failure?

2. Will pharmacologic targeting of primarily Gøαs-coupled GPCR, such as muncaricin M3 acetylcholine receptors (15, 45, 46) be more effective than GLP-1R agonists in preventing or reversing β-cell failure?

3. Would simultaneous stimulation of Gøαs- and Gøq-dependent signaling pathways in promoting β-cell function and survival be superior to stimulation of either pathway alone?

While this article was under peer-review, a newly published study indicates a role for GIP-GIPR in amplifying amino-acid-induced glucagon secretion from islet alpha-cells as an additional mechanism of incretin hormone action (47).

**AUTHOR CONTRIBUTIONS**

All authors contributed to the article and approved the submitted version.

**FUNDING**

Supported in part by NIH DK126011, AG071232, DK20572.

---

**REFERENCES**

1. Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. *J Clin Invest* (2006) 116:1802–12. doi: 10.1172/JCI29103

2. Gerich JE. Is reduced first-phase insulin release the earliest detectable abnormality individuals destined to develop type 2 diabetes? *Diabetes* (2002) 51 Suppl 1:S117–21. doi: 10.2337/diabetes.51.2007.S117

3. Lillioja S, Mott DM, Howard BV, Bennett PH, Yki-Jarvinen H, Freymond D, et al. Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. *N Engl J Med* (1988) 318:1217–25. doi: 10.1056/NEJM198805123181901

4. Vaag A, Henriksen JE, Madsbad S, Holm N, Beck-Nielsen H. Insulin secretion, action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitus. *J Clin Invest* (1995) 95:690–8. doi: 10.1172/JCI117719

5. Ward WK, Boligiano DC, McKnight B, Halter JB, Porte Jr. Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. *J Clin Invest* (1984) 74:1318. doi: 10.1172/JCI111542

6. Odouri OS, Murao N, Shimomura K, Takahashi H, Zhang Q, Dou H, et al. Gs/Gq signaling switch in beta cells defines incretin effectiveness in diabetes. *J Clin Invest* (2020) 130:6639–55. doi: 10.1172/JCI140046

7. Henquin JC. Regulation of insulin secretion: a matter of phase control and amplitude modulation. *Diabetologia* (2009) 52:739–51. doi: 10.1007/s00125-009-1314-y

8. Prentki M, Matschinsky FM, Madiraju SR. Metabolic signaling in fuel-induced insulin secretion. *Cell Metab* (2013) 18:162–85. doi: 10.1016/j.cmet.2013.05.018

9. Prentki M, Matschinsky FM. Ca2+, cAMP, and phospholipid-derived messengers in coupling mechanisms of insulin secretion. *Physiol Rev* (1987) 67:1185–248. doi: 10.1152/physrev.1987.67.4.1185

10. Rorsman P, Ashcroft FM. Pancreatic beta-Cell Electrical Activity and Insulin Secretion: Of Mice and Men. *Physiol Rev* (2018) 98:117–214. doi: 10.1152/physrev.00008.2017

11. Seino S, Shibasaki T, Minami K. Dynamics of insulin secretion and the clinical implications for obesity and diabetes. *J Clin Invest* (2011) 121:2118–25. doi: 10.1172/JCI45680

12. Wollheim CB, Ianjic D, Siegel EG, Kikuchi M, Sharp GW. Importance of cellular calcium stores in glucose-stimulated insulin release. * Ups J Med Sci* (1981) 86:149–64. doi: 10.3109/03007381091792235

13. Wollheim CB, Sharp GW. Regulation of insulin release by calcium. *Physiol Rev* (1981) 61:914–73. doi: 10.1152/physrev.1981.61.4.914

14. Ahren B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. *Nat Rev Drug Discovery* (2009) 8:369–85. doi: 10.1038/nrd2782

15. Jain S, Ruiz de Azaúa I, Lu H, White MF, Guettier JM, Wess J. Chronic activation of a designer G(q)-coupled receptor improves beta cell function. *J Clin Invest* (2013) 123:1750–62. doi: 10.1172/JCI66432

16. Ihala US, Canettieri G, Screenon RA, Kulkarni RN, Krajewski S, Reed J, et al. cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2. *Genes Dev* (2003) 17:1575–80. doi: 10.1101/gad.109713

17. Fujita Y, Sasaki T, Fukui K, Kotani H, Kimura Y, Hata Y, et al. Phosphorylation of Munc-18-n-Secc1rbSec1 by protein kinase C: its implication in regulating the interaction of Munc-18-n-Secc1rbSec1 with syntaxin. *J Biol Chem* (1996) 271:7265–8. doi: 10.1074/jbc.271.13.7265

18. Gao J, Hirata M, Mizokami A, Zhao J, Takahashi I, Takeuchi H, et al. Differential role of SNAP-25 phosphorylation by protein kinases A and C in the regulation of SNARE complex formation and exocytosis in PC12 cells. *Cell Signal* (2016) 28:825–37. doi: 10.1016/j.cellsig.2015.12.014

19. Xie T, Chen M, Zhang QH, Ma Z, Weinstein LS. Beta-cell-specific deficiency of the stimulatory G protein alpha-subunit Galphaql provides a basis for beta cell mass and insulin-resistant diabetes. *Proc Natl Acad Sci USA* (2007) 104:19601–6. doi: 10.1073/pnas.0704796104

20. Sassmann A, Gier B, Groen HF, Drews G, Offermanns S, Wettachueck N. The Gq/ G11-mediated signaling pathway is critical for autocrine potentiation of insulin secretion in mice. *J Clin Invest* (2010) 120:2184–93. doi: 10.1172/JCI43141

21. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. *Gastroenterology* (2007) 132:2131–57. doi: 10.1053/j.gastro.2007.03.054

22. Holst JJ, Knop FK, Vilsboll T, Krarup T, Madsbad S. Loss of incretin effect as a specific, important, and early characteristic of type 2 diabetes. *Diabetes Care* (2011) 34 Suppl 2:S251–7. doi: 10.2337/dc11-0227

23. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. *Am J Physiol Endocrinol Metab* (2004) 287:E199–206. doi: 10.1152/ajpendo.00545.2003

24. Seino S, Shibasaki T. PKA-dependent and PKA-independent pathways for cAMP-regulated exocytosis. *Physiol Rev* (2005) 85:1303–42. doi: 10.1152/physrev.00001.2005

25. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. *Cell Metab* (2018) 27:740–56. doi: 10.1016/j.cmet.2018.03.001
26. Alenkvist I, Gandasi NR, Barg S, Tengholm A. Recruitment of Epac2A to Insulin Grande Docking Sites Regulates Priming for Exocytosis. Diabetes (2017) 66:2610–22. doi: 10.2337/db17-0050
27. Chambers AP, Sorrell JE, Haller A, Roelofs K, Hutch CR, Kim KS, et al. The Role of Pancreatic Preproglucagon in Glucose Homeostasis in Mice. Cell Metab (2017) 25:927–934 e3. doi: 10.1016/j.cmet.2017.02.008
28. Smith EP, An Z, Wagner C, Lewis AG, Cohen EB, Li B, et al. The role of beta cell glucagon-like peptide 1 signaling in glucose regulation and response to diabetes drugs. Cell Metab (2014) 19:1050–7. doi: 10.1016/j.cmet.2014.04.005
29. Capozzi ME, Svendsen B, Encisco SE, Lewandowski SL, Martin MD, Lin H, et al. beta Cell tone is defined by proglucagon peptides through cAMP signaling, JCI Insp (2019) 4:1–16. doi: 10.1172/jci.ins.126742
30. Chepurny OG, Matsoukas MT, Liapakis G, Leech CA, Milliken BT, Doyle RP, et al. Nonconventional glucagon and GLP-1 receptor agonist and antagonist interplay at the GLP-1 receptor revealed in high-throughput FRET assays for cAMP. J Biol Chem (2019) 294:3514–31. doi: 10.1074/jbc.RA118.005682
31. Svendsen B, Larsen O, Gabe MNB, Christiansen CB, Rosenkilde MM, Drucker DJ, et al. Insulin Secretion Depends on Intra-islet Glucagon Signaling. Cell Rep (2018) 25:1127–1134 e2. doi: 10.1016/j.celrep.2018.10.018
32. Zhu L, Dattaroy D, Pham J, Wang L, Barella LF, Cui Y, et al. Intra-islet glucagon signaling is critical for maintaining glucose homeostasis. JCI Insp (2019) 5:1–16. doi: 10.1172/jci.ins.127994
33. Ozcan L, Wong CC, Li G, Xu T, Pajvani U, Park SK, et al. Calcium signaling through CaMKII regulates hepatic glucose production in fasting and obesity. Cell Metab (2012) 15:739–51. doi: 10.1016/j.cmet.2012.03.002
34. Perry RJ, Zhang D, Guerra MT, Brill AL, Goedeke L, Nasiri AR, et al. Glucagon stimulates gluconeogenesis by INSP3R1-mediated hepatic lipolysis. Nature (2020) 579:279–83. doi: 10.1038/s41586-020-2074-6
35. Wang Y, Li G, Goode J, Paz JC, Ouyang K, Screaton R, et al. Insolitol-1,4,5-trisphosphate receptor regulates hepatic gluconeogenesis in fasting and diabetes. Nature (2012) 485:128–32. doi: 10.1038/nature10988
36. Elahi D, McAloon-Dyke M, Fukagawa NK, Menellly GS, Slater AL, Minaker KL, et al. The insulotropic actions of glucose-dependent insulotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept (1994) 51:63–74. doi: 10.1016/0167-0115(94)90136-8
37. Muller TD, Finan B, Bloom SR, D’Alessio D, Drucker DJ, Flatt PR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab (2019) 30:72–130. doi: 10.1016/j.molmet.2019.09.010
38. Naukk MA, Meier JF. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol (2016) 4:525–36. doi: 10.1016/S2213-8587(15)00482-9
39. Basu A, Alzaid A, Dinneen S, Caumo A, Cobelli C, Rizza RA. Effects of a change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and nondiabetic humans in the presence of differing degrees of insulin resistance. J Clin Invest (1996) 99:2351–61. doi: 10.1172/JCI18678
40. Nichols CG. KATP channels as molecular sensors of cellular metabolism. Nature (2006) 440:470–6. doi: 10.1038/nature04711
41. Seino S, Miki T. Physiological and pathophysiological roles of ATP-sensitive K+ channels. Prog Biophys Mol Biol (2003) 83:131–76. doi: 10.1016/S0079-6107(02)00053-6
42. Miki T, Nagashima K, Tashiro F, Kotake K, Yoshitomi H, Tamamoto A, et al. Defective insulin secretion and enhanced insulin action in KATP channel-deficient mice. Proc Natl Acad Sci USA (1998) 95:10402–6. doi: 10.1073/pnas.95.18.10402
43. Remedi MS, Rocheleau IV, Tong A, Patton BL, McDaniel ML, Piston DW, et al. Hyperinsulinism in mice with heterozygous loss of K(ATP) channels. Diabetologia (2006) 49:2368–78. doi: 10.1007/s00125-006-0367-4
44. Shyr ZA, Wang Z, York NW, Nichols CG, Remedi MS. The role of membrane excitability in pancreatic beta-cell glucotoxicity. Sci Rep (2019) 9:6952. doi: 10.1038/s41598-019-43452-8
45. Duttaroy A, Zimilaki CL, Gautam D, Cui Y, Mears D, Wess J. Mucaracine stimulation of pancreatic insulin and glucagon release is abolished in m3 muscarinic acetylcholine receptor-deficient mice. Diabetes (2004) 53:1714–20. doi: 10.2337/diabetes.53.7.1714
46. Zhu L, Rossi M, Doliba NM, Wess J. Beta-cell m3 muscarinic acetylcholine receptors as potential targets for novel antidiabetic drugs. Int Immunopharmacol (2020) 81:106267. doi: 10.1016/j.intimp.2020.106267
47. El K, Gray SM, Capozzi ME, Knuth ER, Jin E, Svendsen B, et al. GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells. Sc Adv (2021) 7(11):1–10.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Hussain, Laimon-Thomson, Mustafa, Deck and Song. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.